Search Count: 8
 |
Crystal Structure Of Human Hdac2 In Complex With Tng260
Organism: Homo sapiens
Method: X-RAY DIFFRACTION Resolution:1.80 Å Release Date: 2025-09-17 Classification: HYDROLASE Ligands: A1B1V, ZN, CA, NHE, EDO, PEG, PGE, PG4 |
Organism: Homo sapiens
Method: X-RAY DIFFRACTION
Release Date: 2025-09-17
Ligands: A1B1V, ZN, CA, NHE, EDO, PEG, PGE, PG4
 |
Improved Feline Drugs As Sars-Cov-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization For Enhanced Bioavailability
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:1.95 Å Release Date: 2022-12-07 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: XTM |
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION
Release Date: 2022-12-07
Ligands: XTM
 |
Peptidomimetic Nitrile Warheads As Sars-Cov-2 3Cl Protease Inhibitors
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.15 Å Release Date: 2021-09-01 Classification: VIRAL PROTEIN Ligands: 4IT |
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION
Release Date: 2021-09-01
Ligands: 4IT
 |
Structure Of Sars-Cov2 3Cl Protease Covalently Bound To Peptidomimetic Inhibitor
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.15 Å Release Date: 2021-07-21 Classification: HYDROLASE/HYDROLASE INHIBITOR Ligands: YWJ, FN7 |
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION
Release Date: 2021-07-21
Ligands: YWJ, FN7
 |
Improved Feline Drugs As Sars-Cov-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization For Enhanced Bioavailability
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:1.90 Å Release Date: 2021-07-07 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: XTJ |
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION
Release Date: 2021-07-07
Ligands: XTJ
 |
Improved Feline Drugs As Sars-Cov-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization For Enhanced Bioavailability
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:1.85 Å Release Date: 2021-07-07 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: XTP |
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION
Release Date: 2021-07-07
Ligands: XTP
 |
Improved Feline Drugs As Sars-Cov-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization For Enhanced Bioavailability
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:1.93 Å Release Date: 2021-07-07 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: XU4 |
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION
Release Date: 2021-07-07
Ligands: XU4
 |
Improved Feline Drugs As Sars-Cov-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization For Enhanced Bioavailability
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.00 Å Release Date: 2021-07-07 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: XV4 |
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION
Release Date: 2021-07-07
Ligands: XV4